PLA2G2D in tumour-draining lymph nodes regulates anti-tumour immunity
In-depth spatial profiling identifies PLA2G2D as a TDLN-centred targetable immune checkpoint for cancer immunotherapy and identifies a specific population of macrophages that express high levels of the enzyme PLA2G2D in tumour-draining lymph nodes that is associated with poor prognosis in patients.